Status:
RECRUITING
Dabrafenib and/or Trametinib Rollover Study
Lead Sponsor:
Novartis Pharmaceuticals
Conditions:
Melanoma
Non Small Cell Lung Cancer
Eligibility:
All Genders
18-100 years
Phase:
PHASE4
Brief Summary
This study is to provide access for patients who are receiving treatment with dabrafenib and/or trametinib in a Novartis-sponsored Oncology Global Development, Global Medical Affairs or a former GSK-s...
Eligibility Criteria
Inclusion
- Patient is currently receiving treatment with dabrafenib/trametinib monotherapy or combination within a Novartis or former GSK sponsored study which has fulfilled the requirements for the primary objective.
- In the opinion of the Investigator would benefit from continued treatment.
Exclusion
- Patient has been previously permanently discontinued from study treatment in the parent protocol.
- Patient's indication is commercially available and reimbursed in the local country.
- Patient currently has unresolved toxicities for which dabrafenib and/or trametinib dosing has been interrupted in the parent study.
Key Trial Info
Start Date :
December 28 2017
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
December 28 2030
Estimated Enrollment :
100 Patients enrolled
Trial Details
Trial ID
NCT03340506
Start Date
December 28 2017
End Date
December 28 2030
Last Update
November 10 2025
Active Locations (27)
Enter a location and click search to find clinical trials sorted by distance.
1
Honor Health Research Institute
Scottsdale, Arizona, United States, 85258
2
National Institute Of Health
Bethesda, Maryland, United States, 20892
3
James Cancer Hospital and Solove Research Institute Ohio State
Columbus, Ohio, United States, 43210
4
Mary Crowley Cancer Research
Dallas, Texas, United States, 75251